Publications

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

 83
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Tags:

Previous Article

Oncogene mutation in colorectal cancer leads to metabolic reprogramming

Next Article

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Related Posts

Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy

Multimodal AI to forecast arrhythmic death in hypertrop...

 66

A b-hydroxybutyrate shunt pathway generates anti- obesity ketone metabolites

A b-hydroxybutyrate shunt pathway generates anti- obesi...

 62

Intrinsic disorder and fuzzy interactions drive multiple functions of HMGB1

Intrinsic disorder and fuzzy interactions drive multipl...

 43